Dual Antithrombotic Therapy With Dabigatran vs Triple Therapy With Warfarin After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation With or Without a Proton Pump Inhibitor (A Prospectively Defined Subgroup Analysis in the RE-DUAL PCI Randomized Trial).

被引：0

作者：

Nicolau, Jose C. ^{[1
]}

Bhatt, Deepak L. ^{[2
]}

Hohnloser, Stefan H. ^{[3
]}

Kimura, Takeshi ^{[4
]}

Lip, Gregory Y. ^{[5
]}

Meide, Corinna ^{[6
]}

Nordaby, Matias ^{[7
]}

Oldgren, Jonas ^{[8
,9
]}

Steg, Philippe ^{[10
]}

ten Berg, Jurrien M. ^{[11
]}

Cannon, Christopher ^{[12
,13
]}

机构：

[1] Univ Sao Paulo, Fac Med, Inst Coracao InCor, Hosp Clin HCFMUSP, Sao Paulo, SP, Brazil

[2] Brigham & Womens Hosp, Boston & Harvard Med Sch, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA

[3] Goethe Univ Frankfurt, Div Cardiol, Dept Med, Frankfurt, Germany

[4] Kyoto Univ, Dept Cardiovasc Med, Kyoto, Japan

[5] Univ Birmingham, Inst Cardiovasc Sci, Birmingham, W Midlands, England

[6] HMS Analyt Software GmbH, Software, Weimar, Lahn, Germany

[7] Boehringer Ingelheim Int GmbH, TA CardioMetab, Ingelheim, Germany

[8] Uppsala Univ, Uppsala Clin Rsch Ctr, Uppsala, Sweden

[9] Uppsala Univ, Dept Med Sci, Uppsala, Sweden

[10] Hop Bichat Claude Bernard, Dept Cardiol, AP HP, Paris, France

[11] St Antonius Hosp, Dept Cardiol, Nieuwegein, Netherlands

[12] Brigham & Womens Hosp, Div Cardiol, Heart & Vasc Ctr, Boston, MA 02115 USA

[13] Harvard Med Sch, Boston, MA 02115 USA

来源：

CIRCULATION | 2018年 / 138卷

关键词：

Antithrombotic therapy; Atrial fibrillation; Coronary artery disease; Dabigatran; Percutaneous coronary intervention (PCI);

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A11775

引用

页数：3

共 50 条

[1] Dual antithrombotic therapy with dabigatran vs triple therapy with warfarin after PCI in patients with atrial fibrillation and diabetes mellitus (a RE-DUAL PCI subgroup analysis)
Maeng, M.
Steg, P. G.
Bhatt, D. L.
Hohnloser, S. H.
Nordaby, M.
Miede, C.
Kimura, T.
Lip, G. Y. H.
Oldgren, J.
Ten Berg, J. M.
Cannon, C. P.
EUROPEAN HEART JOURNAL, 2018, 39 : 1090 - 1091
[2] Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial
Nicolau, Jose C.
Bhatt, Deepak L.
Hohnloser, Stefan H.
Kimura, Takeshi
Lip, Gregory Y. H.
Miede, Corinna
Nordaby, Matias
Oldgren, Jonas
Steg, Philippe Gabriel
ten Berg, Jurrien M.
Godoy, Lucas C.
Cannon, Christopher P.
DRUGS, 2020, 80 (10) : 995 - 1005
[3] Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial
José C. Nicolau
Deepak L. Bhatt
Stefan H. Hohnloser
Takeshi Kimura
Gregory Y. H. Lip
Corinna Miede
Matias Nordaby
Jonas Oldgren
Philippe Gabriel Steg
Jurriën M. ten Berg
Lucas C. Godoy
Christopher P. Cannon
Drugs, 2020, 80 : 995 - 1005
[4] Subgroup Analysis From the RE-DUAL PCI Trial: Dual Antithrombotic Therapy With Dabigatran in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
Oldgren, Jonas
Steg, Philippe-Gabriel
Hohnloser, Stefan H.
Lip, Gregory Y.
Ellis, Stephen G.
Kimura, Takeshi
Nordaby, Matias
ten Berg, Jurrien M.
Bhatt, Deepak L.
Cannon, Christopher P.
Kleine, Eva
CIRCULATION, 2017, 136 (24) : E457 - E457
[5] DUAL ANTITHROMBOTIC THERAPY WITH DABIGATRAN VERSUS TRIPLE THERAPY WITH WARFARIN AFTER PCI IN PATIENTS WITH ATRIAL FIBRILLATION AND DIABETES MELLITUS (A RE-DUAL PCI™ SUBGROUP ANALYSIS)
Ruggieri, G.
EUROPEAN HEART JOURNAL SUPPLEMENTS, 2019, 21 (0E) : E114 - E115
[6] The effect of PCI complexity on the efficacy and safety of dabigatran dual therapy vs warfarin triple therapy in atrial fibrillation: a subgroup analysis from the RE-DUAL PCI trial
Mauri, L.
Steg, P. S.
Bhatt, D. L.
Hohnloser, S. H.
Nordaby, M.
Miede, C.
Kimura, T.
Lip, G. Y. H.
Oldgren, J.
Ten Berg, J. M.
Cannon, C.
EUROPEAN HEART JOURNAL, 2018, 39 : 653 - 653
[7] Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial
Oldgren, Jonas
Steg, Philippe Gabriel
Hohnloser, Stefan H.
Lip, Gregory Y. H.
Kimura, Takeshi
Nordaby, Matias
Brueckmann, Martina
Kleine, Eva
ten Berg, Jurrien M.
Bhatt, Deepak L.
Cannon, Christopher P.
EUROPEAN HEART JOURNAL, 2019, 40 (19) : 1553 - +
[8] The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials)
Eccleston, David S.
Kim, Joseph M.
ten Berg, Jurien M.
Steg, P. Gabriel
Bhatt, Deepak L.
Hohnloser, Stefan H.
de Veer, Anne
Nordaby, Matias
Miede, Corinna
Kimura, Takeshi
Lip, Gregory Y. H.
Oldgren, Jonas
Cannon, Christopher P.
CLINICAL CARDIOLOGY, 2021, 44 (07) : 1002 - 1010
[9] Triple Antithrombotic Therapy With Warfarin or Dual Therapy With Dabigatran According to the Precise-Dapt Score in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Insights From the Re-Dual Pci Trial
Costa, Francesco
Valgimigli, Marco
Steg, Philippe G.
Bhatt, Deepak L.
Hohnloser, Stefan H.
Miede, Corinna
Nordaby, Matias
Lip, Gregory Y.
Oldgren, Jonas
Cannon, Christopher P.
CIRCULATION, 2019, 140
[10] Efficacy and Safety of Dabigatran Dual Therapy vs Warfarin Triple Therapy in Atrial Fibrillation After PCI in Relation to Time in Therapeutic Range: A Subgroup Analysis From the RE-DUAL PCI Trial.
Lip, Gregory Y. H.
Bhatt, Deepak L.
Hohnloser, Stefan H.
Kimura, Takeshi
Meide, Corinna
Nordaby, Matias
Oldgren, Jonas
Steg, Philippe G.
ten Berg, Jurrien M.
Cannon, Christopher
CIRCULATION, 2018, 138

← 1 2 3 4 5 →